A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions

Affiliations

• ¹ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: [email protected].
• ² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
• ³ Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
• ⁴ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
• ⁵ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi University Hospital, ENETS Centers of Excellence, Bologna, Italy.
• ⁶ Department of Cellular Pathology, Northwest London Pathology, Imperial College London NHS Trust, London, UK.
• ⁷ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
• ⁸ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.
• ⁹ Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.